Table 1.

GPCR	Targeting compound	Trade name (if applicable)	Action	Approval status	Reference
GLP1R	Exenatide	Byetta, Bydureon	Incretin mimetic	Approved	[114, 115]
	Liraglutide	Victoza, Saxenda	Incretin mimetic	Approved	[116]
	Albiglutide	Tanzeum	Incretin mimetic	Approved	[117]
	Dulaglutide	Trulicity	Incretin mimetic	Approved	[118, 119]
	Semaglutide		Incretin mimetic	Phase III	[120, 121]
	Lixisenatide	Lyxumia	Incretin mimetic	Phase III completed	[12–124]
	Taspoglutide		Incretin mimetic	Phase III terminated	[125]
	Insulin degludec and liraglutide	iDeg-Lira	Combination	Phase III	[126]
	Insulin glargine and lixisenatide	LixiLan	Combination	Phase III completed	[123]
	Alogliptin	Nesina	DPP4 inhibitor	Approved	[127, 128]
	Saxagliptin	Onglyza	DPP4 inhibitor	Approved	[129]
	Sitagliptin	Januvia	DPP4 inhibitor	Approved	[130]
	Vildagliptin	Galvus	DPP4 inhibitor	Phase III	[131–133]
	Linagliptin	Tradjenta	DPP4 inhibitor	Approved	[134]
	Gemigliptin		DPP4 inhibitor	Phase III	[135–137]
GPR40	Fasiglifam (Tak-875)		GPR 40 agonist	Phase III Terminated	Reviewed in [138]
D2R	Bromocriptine	Cycloset	Reduces HbA1C		[63, 70]
CpepR	C-peptide	Ersatta	CpepR agonist	Phase IIb	[139]

GPCR, G protein-coupled receptor.